For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
The Canadian Institutes of Health Research recently announced the recipients of the Clinical Trials Fund. The Canadian Cancer Trials Group with study lead Dr Elena Elimova at Princess Margaret Cancer Centre were granted $3,744,953 over 3 years to fund the CCTG GA4 study in HER2 overexpressing advanced gastroesophageal adenocarcinoma.
OV25: A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women with BRCA 1/2 Mutations (STICs and STONEs) has been closed to accrual. 117 of the planned 414 patients were randomized (80 from Can
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating stage III or stage IV Hodgkin's lymphoma.
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:
The entire CCTG team extends a warm welcome to Dr Mariam Jafri who has recently joined us as a Senior Investigator. Dr Jafri was a consultant in Medical Oncology at the University Hospital Birmingham. She has specific expertise in breast cancer, germ cell tumours, sarcoma and Adolescent and Young Adults (AYA) with cancer with particular interest in using genomics to tailor treatment to patients. Dr Jafri completed her oncology specialty training in the West Midlands and Oxford U.K. and two research fellowships which culminated in her receiving a Ph.D. in the molecular biology of cancer.
IND234 substudy D: A Phase II Study of CFI-400945 Fumarate in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - A Substudy of IND234 is closed to accrual however this substudy, treatment and follow up of patients will continue according to the protocol. Please note the IND234 main study and other substudies remain open to accrual.
EN10 (RAINDO BLUE & TAPER) is a new Canadian clinical trial that is applying state-of-the-art molecular testing to classify post-surgery treatments in early-stage endometrial cancer.
The purpose of this study is to identify people at low risk of cancer recurrence based on the molecular features of their tumours. These individuals may safely receive less radiotherapy or may require no radiotherapy or chemotherapy after surgery.
